凝血酶
直接凝血酶抑制剂的发现与发展
适体
阿加曲班
药理学
化学
水蛭素
抗凝剂
凝结
抗凝药
纤维蛋白
凝血活酶
直接凝血酶抑制剂
生物化学
肝素
血小板
医学
华法林
分子生物学
生物
免疫学
达比加群
内科学
心房颤动
作者
Elena Zavyalova,N. B. Ustinov,Andrey V. Golovin,Galina Pavlova,А. М. Копылов
标识
DOI:10.2174/0929867323666160517120126
摘要
Thrombin is a key enzyme of blood coagulation system which has multiple functions including pro- and anticoagulant, platelet aggregating and inflammatory activities. Unsurprisingly, this enzyme has been a target for anticoagulant drug development for decades. Among the most interesting direct thrombin inhibitors with intravenous administration route are the following ones: 1) hirudins, proteins with bivalent binding mode to the thrombin, 2) bivalirudin, the peptide with bivalent binding mode to the thrombin, 3) argatroban, the chemical that binds to the thrombin active site, and 4) G-quadruplex DNA aptamers, structured oligonucleotides with an affinity to protein-binding site of the thrombin. Efficiency of all these inhibitors has been studied in vivo in preclinical and clinical trials, as well as in vitro with various tests, allowing to compare them thoroughly. In the review three levels of comparison were used to highlight the features of each inhibitor: 1) thrombin inhibition constants as a characteristic of inhibitor potency in simple enzymatic system; 2) inhibition of fibrin fiber formation and thrombin generation in coagulation cascade as a characteristic of anticoagulant potency in human blood plasma; and 3) therapeutic doses used and therapeutic profiles obtained after intravenous administration into animals and humans. The data clearly demonstrate weak and strong aspects of thrombin binding aptamers providing a solid background for further novel anticoagulant development. Keywords: Anticoagulant, Aptamer, Coagulation, Inhibitor, Thrombin, Thrombin generation test.
科研通智能强力驱动
Strongly Powered by AbleSci AI